Obesity drugs tied to more muscle loss vs. other weight loss interventions

SAN FRANCISCO — Incretin-based obesity medications may result in higher muscle-related loss vs. other weight loss strategies, according to data published in Annals of Internal Medicine.
The findings “suggest that while weight loss led to known losses of muscle-based parameters, the proportion of muscle lost relative to total weight lost was higher in those taking incretins, and even higher in studies using semaglutide and tirzepatide,” John A. Batsis, MD, an associate professor at the University of North Carolina at Chapel Hill, told Healio. “In addition, our analysis did not find any studies








